<DOC>
	<DOCNO>NCT00209118</DOCNO>
	<brief_summary>A.OVERVIEW This 26 week study examine ability paroxetine ( Paxil ) prevent development depression neurotoxicity patient receive either 3 million unit subcutaneous IFN ( interferon-alpha-2b ) 3 times/week ( plus ribavirin , 1000-1200 mg/d ) ) PEG ( polyethylene glycol ) interferon-alpha-2b ( 1.5 micrograms/kg one time week ) ribavirin ( 800 1,400 mg day ) chronic hepatitis C ( CHC ) . The IFN plasma half life ( t1/2 24 34 hour ) PEG , CHC treatment recently approve FDA , significantly prolong allow week dose . Studies indicate side effect profile two form IFN-alpha treatment similar . CHC patient screen study eligibility , total 100 CHC patient age 18 65 year old enrol across three site ( 30 Emory site combination 30 University Pennsylvania , Rush-Presbyterian-Saint Lukes Medical Center Chicago Montefiore Medical Center New York . ) Two week prior treatment subcutaneous IFN-alpha-2b , patient meet inclusion exclusion criterion stratify basis history major depression randomly assign paroxetine placebo double blind fashion .</brief_summary>
	<brief_title>Paroxetine Treatment Interferon Related Side Effects Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>age 1865 year include male , female minority serum positive either antiHCV antibody HCVRNA positive PCR compensate liver disease follow minimum hematologic biochemical criterion : hemoglobin 3 g/dl male ; 12 g/dl female , white blood cell count &gt; 3,000/mm3 , neutrophil count &gt; 1,5000/mm3 , platelet &gt; 100,000/mm3 , prothrombin time 2 second prolonged compare control , equivalent INR ratio , albumin stable within normal limit , serum creatinine within normal limit , thyroidstimulating hormone ( TSH ) within normal limit , direct bilirubin 0.3 mg/dl within 20 % upper limit normal ( ULN ) local laboratory , indirect bilirubin 0.8 mg/dl within 20 % ULN local laboratory , fast blood sugar 115 mg/dl within 20 % ULN nondiabetic patient serum hepatitis B surface antigen ( HbsAg ) negative , antinuclear antibody ( ANA ) 1:320 normal pretherapy ocular examination history diabetes hypertension hemoglobin A1C &lt; 8.5 % history diabetes negative pregnancy test woman childbearing potential , consent adhere adequate contraception monogamous relationship male partner vasectomy treatment period 6 month discontinuation therapy breast feed documentation confirmation adequate contraception sexually active male free psychotropic medication minimum 14 day prior baseline visit ( 8 week fluoxetine ) actively meet criterion major depression within past six month active , effective treatment depression antidepressant within past three month meet criterion schizophrenia bipolar disorder ( mania ) past present actively meet DSM IV criterion substance abuse/dependence within past six month psychotropic medication within 14 day prior baseline visit ( 8 week fluoxetine ) evidence untreated poorly control endocrine , cardiovascular , hematological , renal , neurological disease evidence decompensated liver disease ( history presence ascites , bleed varix , spontaneous encephalopathy ) history CNS trauma active seizure disorder require medication cause liver disease chronic hepatitis C , coinfection hepatitis B virus and/or human immunodeficiency virus , hemochromatosis , Wilson 's disease prior treatment ( IFNalpha ribavirin ) immunomodulatory drug , include corticosteroid within 6 month entry protocol clinical gout know hypersensitivity alpha interferon ribavirin hemoglobinopathy ( e.g . thalassemia ) positive pregnancy test clinically significant retinal abnormality organ transplant score &lt; 24 Mini Mental Status Exam ( MMSE ) prior history severe adverse event associate paroxetine condition opinion investigator would make patient unsuitable enrollment , could interfere participate complete protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Interferon-alpha associated side effect</keyword>
	<keyword>Antidepressants</keyword>
	<keyword>Prevention</keyword>
</DOC>